Cerecor Inc logo

CERC - Cerecor Inc Share Price

$2.52 0.1  4.1%

Last Trade - 27/11/20

Sector
Healthcare
Size
Small Cap
Market Cap £133.5m
Enterprise Value £108.5m
Revenue £4.33m
Position in Universe 3985th / 6429
Bullish
Bearish
Unlock CERC Revenue
Momentum
Relative Strength (%)
1m -2.48%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -61.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 1.15 27.8 7.03 6.75 6.60 4.00
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, CerecorInc revenues decreased 16% to $5.2M. Net loss beforeextraordinary items increased from $10.6M to $48.2M.Revenues reflect License and other revenue decrease from$100K to $0K. Higher net loss reflects Acquired in-processresearch and develop increase from $0K to $25.5M (expense),Research and Development - Balancing val increase from $7Mto $14.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CERC Revenue Unlock CERC Revenue

Net Income

CERC Net Income Unlock CERC Revenue

Normalised EPS

CERC Normalised EPS Unlock CERC Revenue

PE Ratio Range

CERC PE Ratio Range Unlock CERC Revenue

Dividend Yield Range

CERC Dividend Yield Range Unlock CERC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CERC EPS Forecasts Unlock CERC Revenue
Profile Summary

Cerecor, Inc. is a biopharmaceutical company. The Company is focused on development and commercialization of treatments for pediatric and orphan diseases. Its pediatric rare disease pipeline is led by CERC-801, CERC-802 and CERC-803 (CERC-800 programs), which are therapies for inborn errors of metabolism, specifically disorders known as Congenital Disorders of Glycosylation (CDGs). The Company is also developing CERC-002, CERC-006 and CERC-007. CERC-007 is an anti-IL-18 monoclonal antibody which is developed for autoimmune inflammatory diseases such as Adult Onset Stills Disease (AOSD) and Multiple Myeloma. CERC-006 is an mTORC1/2 inhibitor which is developed as a treatment for Lymphatic Malformations (LM). CERC-002 is an anti-LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes), monoclonal antibody is developed as a treatment for Pediatric Crohn's Disease.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated January 31, 2011
Public Since November 13, 2015
No. of Shareholders: 64
No. of Employees: 18
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 74,910,047
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CERC Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CERC
Upcoming Events for CERC
Tuesday 9th March, 2021 Estimate
Q4 2020 Cerecor Inc Earnings Release
Wednesday 5th May, 2021 Estimate
Q1 2021 Cerecor Inc Earnings Release
Frequently Asked Questions for Cerecor Inc
What is the Cerecor Inc share price?

As of 27/11/20, shares in Cerecor Inc are trading at $2.52, giving the company a market capitalisation of £133.5m. This share price information is delayed by 15 minutes.

How has the Cerecor Inc share price performed this year?

Shares in Cerecor Inc are currently trading at $2.52 and the price has moved by -29.59% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Cerecor Inc price has moved by -38.19% over the past year.

What are the analyst and broker recommendations for Cerecor Inc?

Of the analysts with advisory recommendations for Cerecor Inc, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Cerecor Inc is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Cerecor Inc next release its financial results?

Cerecor Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Cerecor Inc dividend yield?

Cerecor Inc does not currently pay a dividend.

Does Cerecor Inc pay a dividend?

Cerecor Inc does not currently pay a dividend.

When does Cerecor Inc next pay dividends?

Cerecor Inc does not currently pay a dividend.

How do I buy Cerecor Inc shares?

To buy shares in Cerecor Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Cerecor Inc?

Shares in Cerecor Inc are currently trading at $2.52, giving the company a market capitalisation of £133.5m.

Where are Cerecor Inc shares listed? Where are Cerecor Inc shares listed?

Here are the trading details for Cerecor Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: CERC
What kind of share is Cerecor Inc?

Based on an overall assessment of its quality, value and momentum, Cerecor Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Cerecor Inc share price forecast 2020?

Shares in Cerecor Inc are currently priced at $2.52. At that level they are trading at 0.362% discount to the analyst consensus target price of 0.00.

Analysts covering Cerecor Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.75 for the next financial year.

How can I tell whether the Cerecor Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cerecor Inc. Over the past six months, the relative strength of its shares against the market has been -30.76%. At the current price of $2.52, shares in Cerecor Inc are trading at -7.63% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Cerecor Inc PE Ratio?

We were not able to find PE ratio data for Cerecor Inc.

Who are the key directors of Cerecor Inc?

Cerecor Inc's management team is headed by:

Phil Gutry - IND
Steven Boyd - IND
Joseph Miller - DRC
Jamie Harrell - OTH
Sol Barer - CHM
Michael Cola - CEO
Garry Neil - OTH
Jeff Wilkins - OTH
Suzanne Bruhn - DRC
Christopher Sullivan - CFO
Who are the major shareholders of Cerecor Inc?

Here are the top five shareholders of Cerecor Inc based on the size of their shareholding:

Armistice Capital LLC Hedge Fund
Percentage owned: 40.07% (30.0m shares)
Nantahala Capital Management, LLC Hedge Fund
Percentage owned: 7.73% (5.79m shares)
Fremantle Corporation Corporation
Percentage owned: 4.67% (3.50m shares)
Opaleye Management Inc. Hedge Fund
Percentage owned: 4.5% (3.37m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 2.9% (2.17m shares)
Similar to CERC
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.